article thumbnail

Generative AI: Revolutionizing Pharmaceutical Industry and Driving Precision Medicine With Innovation, Equity and Ethics

MedCity News

The art of processing and producing valuable data, empowers researchers to identify potential drug targets, predict drug interactions, and optimize clinical trial designs, reducing time and costs associated with research endeavors and ultimately bringing the best quality medicines to meet our needs at a faster pace.

Ethics 293
article thumbnail

How Artificial Intelligence Could Be the Ultimate Weapon Against Cancer

MedCity News

One example of how AI is already being used to personalize cancer treatment is in the field of precision medicine. Precision medicine involves tailoring treatments to a patient’s unique genetic makeup, disease profile and lifestyle.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Canadian and US developers to trial psychedelic medicines in UK

European Pharmaceutical Review

The UK’s regulatory pathway and fast-track drug approval process enables companies to fast-track their ethics applications and combine their reviews. The regulators are the Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) respectively.

Medicine 105
article thumbnail

KCL’s mini liver model promises more effective drug testing method

PharmaTimes

The method provides a more accurate and ethical approach to drug testing for medicines

Ethics 119
article thumbnail

Pharma Research Trends: Leveraging Innovation for Smarter Marketing Strategies

Pharma Marketing Network

From AI-powered insights to the rise of precision medicine, new trends are reshaping the way we connect with patients and healthcare providers. Precision Medicine: Targeting the Right Audience Precision medicine, with its focus on individualized treatment, offers a goldmine of opportunities for marketers.

article thumbnail

Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets

PM360

Access to medicines have persisting and systemic differences across the globe and within countries. It is estimated that nearly two billion people globally do not have access to essential medicines. Traditionally, pharmaceutical companies have not prioritized emerging markets as part of their access strategy.

article thumbnail

Staying abreast of regulations with NGS?based viral safety for faster, safer and more ethical lot release of our vaccines

European Pharmaceutical Review

Safety is key to the development of any medicine, but the safety considerations linked to bioproduction are more complex because biologics are more sophisticated medicines than small molecules. First, we see a global trend of developing more ethical solutions for the safety testing of biologics. Available from: [link].

Ethics 98